Legal & General Group Plc Sells 16,053 Shares of Halozyme Therapeutics, Inc. $HALO

Legal & General Group Plc lessened its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 318,366 shares of the biopharmaceutical company’s stock after selling 16,053 shares during the period. Legal & General Group Plc’s holdings in Halozyme Therapeutics were worth $21,426,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of HALO. Empowered Funds LLC bought a new stake in Halozyme Therapeutics during the 1st quarter worth approximately $755,000. Acadian Asset Management LLC bought a new position in shares of Halozyme Therapeutics in the 1st quarter worth $195,000. Hsbc Holdings PLC increased its holdings in shares of Halozyme Therapeutics by 117.1% in the 2nd quarter. Hsbc Holdings PLC now owns 10,102 shares of the biopharmaceutical company’s stock worth $522,000 after buying an additional 5,448 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 6.9% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,685 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 174 shares during the last quarter. Finally, Baird Financial Group Inc. increased its holdings in shares of Halozyme Therapeutics by 6.2% in the 2nd quarter. Baird Financial Group Inc. now owns 11,090 shares of the biopharmaceutical company’s stock worth $577,000 after buying an additional 650 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HALO. HC Wainwright increased their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, April 29th. Benchmark increased their price target on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 19th. Wells Fargo & Company increased their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a report on Thursday, February 19th. Wall Street Zen raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Finally, TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Wednesday, February 18th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the firm’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the sale, the director owned 38,498 shares of the company’s stock, valued at $2,443,853.04. This trade represents a 4.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. Following the completion of the sale, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $53,122,698.20. This trade represents a 1.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 100,482 shares of company stock valued at $6,807,042 in the last quarter. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO stock opened at $66.54 on Monday. The company has a debt-to-equity ratio of 8.81, a quick ratio of 2.33 and a current ratio of 2.76. Halozyme Therapeutics, Inc. has a 52 week low of $51.06 and a 52 week high of $82.22. The firm’s fifty day moving average is $66.14 and its 200 day moving average is $68.76. The firm has a market cap of $7.89 billion, a P/E ratio of 23.94, a P/E/G ratio of 0.27 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The company had revenue of $376.71 million for the quarter, compared to analyst estimates of $358.60 million. During the same quarter last year, the firm earned $1.11 EPS. The firm’s quarterly revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 7.6 earnings per share for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.